ID

19654

Beschreibung

Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98; ODM derived from: https://clinicaltrials.gov/show/NCT00899288

Link

https://clinicaltrials.gov/show/NCT00899288

Stichworte

  1. 19.01.17 19.01.17 -
  2. 02.09.21 02.09.21 -
Hochgeladen am

19. Januar 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00899288

Eligibility Breast Cancer NCT00899288

Criteria
Beschreibung

Criteria

enrolled on protocol ibcsg-1-98
Beschreibung

Enrollment

Datentyp

boolean

Alias
UMLS CUI [1]
C1516879
currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol ibcsg-1-98
Beschreibung

Tamoxifen | letrozole | Additional Therapy Expected

Datentyp

boolean

Alias
UMLS CUI [1]
C0039286
UMLS CUI [2]
C0246421
UMLS CUI [3,1]
C1706712
UMLS CUI [3,2]
C1517001
no recurrent breast cancer or second primary cancer
Beschreibung

Breast cancer recurrent | Second Primary Cancers

Datentyp

boolean

Alias
UMLS CUI [1]
C0278493
UMLS CUI [2]
C0751623
no known bone disease (including osteomalacia or osteogenesis imperfecta)
Beschreibung

Bone Diseases | Osteomalacia | Osteogenesis Imperfecta

Datentyp

boolean

Alias
UMLS CUI [1]
C0005940
UMLS CUI [2]
C0029442
UMLS CUI [3]
C0029434
hormone receptor status
Beschreibung

Hormone Receptor Status

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
estrogen and/or progesterone receptor positive tumor
Beschreibung

Estrogen receptor positive tumor | Progesterone receptor positive tumor

Datentyp

boolean

Alias
UMLS CUI [1]
C1562312
UMLS CUI [2]
C1562928
patient characteristics:
Beschreibung

Client Characteristics

Datentyp

boolean

Alias
UMLS CUI [1]
C0815172
female
Beschreibung

Gender

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
postmenopausal
Beschreibung

Postmenopausal state

Datentyp

boolean

Alias
UMLS CUI [1]
C0232970
no uncontrolled thyroid or parathyroid disease, cushing's disease, or other pituitary diseases
Beschreibung

Thyroid Disease Uncontrolled | Parathyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0040128
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0030517
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0221406
UMLS CUI [4]
C0032002
no malabsorption syndrome or clinically relevant vitamin d deficiency
Beschreibung

Malabsorption Syndrome | Vitamin D Deficiency Relevant Clinical

Datentyp

boolean

Alias
UMLS CUI [1]
C0024523
UMLS CUI [2,1]
C0042870
UMLS CUI [2,2]
C2347946
UMLS CUI [2,3]
C0205210
prior concurrent therapy:
Beschreibung

Therapeutic procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Beschreibung

disease characteristic

Datentyp

boolean

Alias
UMLS CUI [1]
C0599878
more than 1 year since prior and no concurrent anticonvulsants
Beschreibung

Anticonvulsants

Datentyp

boolean

Alias
UMLS CUI [1]
C0003286
more than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
Beschreibung

Adrenal Cortex Hormones Dose | Prednisone U/day

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0456683
no prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
Beschreibung

Sodium Fluoride Dose U/day

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0037508
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0456683
more than 12 months since prior and no concurrent anabolic steroids
Beschreibung

Anabolic steroids

Datentyp

boolean

Alias
UMLS CUI [1]
C0002744
more than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin d])
Beschreibung

Pharmaceutical Preparations Prevention Osteoporosis | Calcium | Cholecalciferol | Vitamin D

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2700409
UMLS CUI [1,3]
C0029456
UMLS CUI [2]
C0006675
UMLS CUI [3]
C0008318
UMLS CUI [4]
C0042866
concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
Beschreibung

Warfarin

Datentyp

boolean

Alias
UMLS CUI [1]
C0043031

Ähnliche Modelle

Eligibility Breast Cancer NCT00899288

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Enrollment
Item
enrolled on protocol ibcsg-1-98
boolean
C1516879 (UMLS CUI [1])
Tamoxifen | letrozole | Additional Therapy Expected
Item
currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol ibcsg-1-98
boolean
C0039286 (UMLS CUI [1])
C0246421 (UMLS CUI [2])
C1706712 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
Breast cancer recurrent | Second Primary Cancers
Item
no recurrent breast cancer or second primary cancer
boolean
C0278493 (UMLS CUI [1])
C0751623 (UMLS CUI [2])
Bone Diseases | Osteomalacia | Osteogenesis Imperfecta
Item
no known bone disease (including osteomalacia or osteogenesis imperfecta)
boolean
C0005940 (UMLS CUI [1])
C0029442 (UMLS CUI [2])
C0029434 (UMLS CUI [3])
Hormone Receptor Status
Item
hormone receptor status
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Estrogen receptor positive tumor | Progesterone receptor positive tumor
Item
estrogen and/or progesterone receptor positive tumor
boolean
C1562312 (UMLS CUI [1])
C1562928 (UMLS CUI [2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Postmenopausal state
Item
postmenopausal
boolean
C0232970 (UMLS CUI [1])
Thyroid Disease Uncontrolled | Parathyroid Disease Uncontrolled | Cushing's disease | Pituitary Diseases
Item
no uncontrolled thyroid or parathyroid disease, cushing's disease, or other pituitary diseases
boolean
C0040128 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0030517 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0221406 (UMLS CUI [3])
C0032002 (UMLS CUI [4])
Malabsorption Syndrome | Vitamin D Deficiency Relevant Clinical
Item
no malabsorption syndrome or clinically relevant vitamin d deficiency
boolean
C0024523 (UMLS CUI [1])
C0042870 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C0205210 (UMLS CUI [2,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])
Anticonvulsants
Item
more than 1 year since prior and no concurrent anticonvulsants
boolean
C0003286 (UMLS CUI [1])
Adrenal Cortex Hormones Dose | Prednisone U/day
Item
more than 6 months since prior and no concurrent corticosteroids at doses > the equivalent of 5 mg/day of prednisone for > 2 weeks total
boolean
C0001617 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
Sodium Fluoride Dose U/day
Item
no prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for > 1 month
boolean
C0037508 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Anabolic steroids
Item
more than 12 months since prior and no concurrent anabolic steroids
boolean
C0002744 (UMLS CUI [1])
Pharmaceutical Preparations Prevention Osteoporosis | Calcium | Cholecalciferol | Vitamin D
Item
more than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin d])
boolean
C0013227 (UMLS CUI [1,1])
C2700409 (UMLS CUI [1,2])
C0029456 (UMLS CUI [1,3])
C0006675 (UMLS CUI [2])
C0008318 (UMLS CUI [3])
C0042866 (UMLS CUI [4])
Warfarin
Item
concurrent warfarin allowed provided duration of treatment is no more than 4 weeks
boolean
C0043031 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video